Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BioHarvest Sciences ( (BHST) ) just unveiled an announcement.
BioHarvest Sciences Inc. announced its participation in the Canaccord Genuity 45th Annual Growth Conference, where CEO Ilan Sobel will engage with institutional investors and present the company’s growth plans. This event highlights BioHarvest’s momentum in scaling its consumer and CDMO businesses, potentially enhancing its industry position and stakeholder value.
The most recent analyst rating on (BHST) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on BioHarvest Sciences stock, see the BHST Stock Forecast page.
Spark’s Take on BHST Stock
According to Spark, TipRanks’ AI Analyst, BHST is a Neutral.
BioHarvest Sciences exhibits strong revenue growth and operational improvements, as highlighted in the earnings call. However, substantial financial challenges, such as negative equity and reliance on external funding, pose significant risks. Technical indicators suggest potential positive momentum, but valuation remains unattractive due to negative earnings and no dividend yield.
To see Spark’s full report on BHST stock, click here.
More about BioHarvest Sciences
BioHarvest Sciences Inc. is a leader in Botanical Synthesis, utilizing its patented technology platform to produce plant-based compounds without growing the actual plants. The company operates in two main business areas: as a contract development and manufacturing organization (CDMO) for novel plant-based compounds, and as a creator of proprietary nutraceutical health and wellness products, including dietary supplements.
Average Trading Volume: 13,561
Technical Sentiment Signal: Buy
Current Market Cap: $119.6M
See more data about BHST stock on TipRanks’ Stock Analysis page.